Gilead Sciences (GILD) Offering Possible 15.74% Return Over the Next 10 Calendar Days

Gilead Sciences's most recent trend suggests a bearish bias. One trading opportunity on Gilead Sciences is a Bear Call Spread using a strike $70.00 short call and a strike $75.00 long call offers a potential 15.74% return on risk over the next 10 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $70.00 by expiration. The full premium credit of $0.68 would be kept by the premium seller. The risk of $4.32 would be incurred if the stock rose above the $75.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Gilead Sciences is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Gilead Sciences is bearish.

The RSI indicator is at 22.74 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Gilead Sciences

A Big Pension Bought GE, Merck, and Intel Stock. It Sold This Biotech.
Sun, 09 Aug 2020 11:00:00 +0000
The State of Michigan Retirement System bought more General Electric, Merck, and Intel stock in the second quarter, and sold most of its investment in biotech stock Gilead Sciences.

These Chip Stocks Jumped On Upbeat Earnings Reports
Fri, 07 Aug 2020 20:23:24 +0000
Amid a mixed week for chip company earnings, two semiconductor stocks got a boost from beat-and-raise reports. SiTime and Synaptics cheered investors with their results and guidance.

Pfizer to Produce Gilead Virus-Treatment Candidate Remdesivir
Fri, 07 Aug 2020 16:02:00 +0000
Pfizer signed a multi-year agreement to produce Gilead Sciences' coronavirus-treatment candidate remdesivir.

Pfizer Will Help Gilead Sciences Make Its Covid-19 Treatment, Remdesivir
Fri, 07 Aug 2020 15:04:00 +0000
The drug giant is one of the firms that will manufacture remdesivir, Gilead Sciences’ experimental antiviral that got emergency approval in May as a treatment for Covid-19.

Pfizer, Gilead Strike Multiyear Partnership To Manufacture COVID-19 Drug Remdesivir
Fri, 07 Aug 2020 14:07:29 +0000
Large-cap biopharma companies Pfizer Inc. (NYSE: PFE) and Gilead Sciences, Inc. (NASDAQ: GILD) announced a deal Friday for GIlead's remdesivir, which has been accorded emergency use authorization by the FDA for treating COVID-19.The Pfizer-Gilead Partnership: Pfizer said it has entered a multiyear agreement with Gilead to manufacture and supply Gilead's investigational antiviral remdesivir, as it joins a host of companies lending a helping hand to scale up the supply of coronavirus drugs. The agreement calls for Pfizer to provide contract manufacturing services at its McPherson, Kansas facility to manufacture and supply remdesivir.The partnership is in line with a five-point plan Pfizer announced in May that calls on biopharma and biotech companies, government agencies and academia to work together to tackle the COVID-19 crisis.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Why It's Important: Pfizer's finance, manpower, expertise and know-how should come in handy for manufacturing the antiviral drug at scale."As one of the largest manufacturers of vaccines, biologics and sterile injectables, it is a privilege to offer our expertise and infrastructure to help fight this pandemic. In that spirit, we are pleased that Gilead is using our manufacturing capacity to help facilitate supply of this medicine to patients as quickly as possible," Albert Bourla, Pfizer chairman and CEO, said in a statement. Gilead said Thursday that it has expanded its global network of internal manufacturing sites and external organizations, including partnering with industry peers, to add manufacturing capacity for remdesivir globally. The drug's trade name is Veklury. "Our Veklury manufacturing network now includes more than 40 companies in North America, Europe and Asia," according to Gilead. PFE, GILD Price Action: At last check, Pfizer shares were trading down slightly at $38.26, while Gilead shares were up 0.66% at $69.26.See more from Benzinga * The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs * Moderna Analyst Breaks Down Biopharma's Coronavirus Vaccine Pricing * Johnson & Johnson Clinches Coronavirus Vaccine Deal With US Government: B, 100M Doses(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.